



## The Advanced Practitioner's Guide to Multiple Myeloma

A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

**Release date:** March 15, 2016

**Estimated time to complete activity:** 3 hours

**Expiration date:** March 15, 2017

### Annenberg Center for Health Sciences at Eisenhower

39000 Bob Hope Drive, Dinah Shore Bldg.  
Rancho Mirage, CA 92270  
Voice: 760-773-4500  
Fax: 760-773-4513  
E-mail: [contactce@annenberg.net](mailto:contactce@annenberg.net)

### Journal of the Advanced Practitioner in Oncology

94 North Woodhull Road  
Huntington, NY 11743  
Voice: 631-692-0800  
Fax: 631-692-0805  
E-mail: [claudine@harborsidepress.com](mailto:claudine@harborsidepress.com)

© 2016, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This supplement is provided by independent educational grants from the following companies: Takeda Oncology, Celgene Corporation, Binding Site, and Adaptive Biotechnologies.

### Faculty

**Page Bertolotti, RN, BSN, OCN**, Samuel Oschin Cancer Center at Cedars-Sinai Medical Center

**Kevin Brigle, PhD, NP**, VCUHS Massey Cancer Center

**Donna D. Catamero, ANP-BC, OCN, CCRC**, Mount Sinai Medical Center

**Kathleen Colson, RN, BSN, BS**, Dana-Farber Cancer Center

**Hollie Devine, MSN, ANP-BC**, The Ohio State University Medical Center James Cancer Hospital

**Deborah Doss, RN, OCN**, Dana-Farber Cancer Center

**Beth Faiman, PhD, MSN, APRN-BC, AOCN**, Cleveland Clinic Taussig Cancer Institute

**Elizabeth Finley-Oliver, RN, BSN, OCN**, H. Lee Moffitt Cancer Center and Research Institute

**Charise Gleason, MSN, NP-BC, AOCNP**, Winship Cancer Institute of Emory University

**Sandra Kurtin, RN, MSN, AOCN, ANP-C**, The University of Arizona Cancer Center

**Patricia A. Mangan, RN, MSN, APRN-BC**, Abramson Cancer Center at the University of Pennsylvania

**Ali McBride, PharmD, MS, BCPS, BCOP**, The University of Arizona Cancer Center

**Ann McNeill, RN, MSN, APN**, John Theurer Cancer Center at HUMC

**Teresa Miceli, RN, BSN, OCN**, Mayo Clinic-Rochester

**Kimberly Noonan, RN, ANP, AOCN**, Dana-Farber Cancer Center

**Tiffany Richards, MS, ANP, AOCNP**, MD Anderson Cancer Center

**Sandra Rome, RN, MN, AOCN, CNS**, Cedars-Sinai Medical Center

**Joseph Tariman, PhD, ANP-BC**, DePaul University

**Daniel Verina, BS, BSN, MSN, ACNP-BC**, Mount Sinai Medical Center

### Activity Rationale and Purpose

Managing the patient with multiple myeloma (MM) across the continuum of care is challenging given the heterogeneity of the population, the older age of most patients with MM, and the rapidly changing treatment landscape. Many practices in the community or rural settings see relatively few MM patients. This supplement to JADPRO will provide the advanced practitioner in oncology and other oncology professionals with state-of-the-science information they need to effectively manage the patient with MM.

## Intended Audience

The activity's target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

## Learning Objectives

After completing this educational activity, participants should be able to:

1. Describe the significance of minimal residual disease, continuous treatment, and sequencing of treatment relative to improving long-term outcomes for patients with multiple myeloma (MM)
2. Integrate palliative and supportive care strategies throughout the MM continuum of care
3. Identify clinical tools for support of the advanced practitioner in the clinical management of MM
4. Articulate key aspects of the updated International Myeloma Working Group guidelines for diagnosis and monitoring of MM
5. Differentiate the various stages of MM with recommended approaches to treatment
6. Apply the principle of adherence, persistence, and treatment fatigue to the care of MM patients and their caregivers
7. Incorporate risk-adapted treatment strategies into the treatment of MM across the continuum of care
8. Identify the key aspects of efficacy and safety, including drug-drug, drug-food interactions, and recommendations for dose modification, for new agents in the treatment of MM, including monoclonal antibodies and oral agents

## Continuing Education

**Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.**



**Physicians.** This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the International Myeloma Foundation. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 3 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**Nurses.** Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 3.0 contact hours may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 3 contact hours.



**Pharmacists.** The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-16-024-H04-P. This program is designated for up to 3.0 contact hours (0.3 CEUs) of continuing pharmacy education credit.

## Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

## Disclosures

### FACULTY

**Page Bertolotti, RN, BSN, OCN**, has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, and Amgen.

**Kevin Brigle, PhD, NP**, has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, and Amgen.

**Donna D. Catamero, ANP-BC, OCN, CCRC**, has acted as a consultant for Celgene and Takeda, and has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, Amgen, Novartis, and Janssen.

**Kathleen Colson, RN, BSN, BS**, has acted as a consultant for Celgene, Takeda, and Amgen.

**Hollie Devine, MSN, ANP-BC**, has no potential conflicts of interest to disclose.

**Deborah Doss, RN, OCN**, has acted as a consultant for Celgene, Takeda, Amgen, and Bristol-Myers Squibb, and has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, and Amgen.

**Beth Faiman, PhD, MSN, APRN-BC, AOCN**, has acted as a consultant, a lecturer, and served on speakers bureaus for Celgene, Takeda, and Amgen.

**Elizabeth Finley-Oliver, RN, BSN, OCN**, has acted as a consultant for Takeda, Amgen, and Celgene, and has acted as a lecturer and served on speakers bureaus for Celgene.

**Charise Gleason, MSN, NP-BC, AOCNP**, has acted as a consultant for Celgene and Takeda.

**Sandra Kurtin, RN, MSN, AOCN, ANP-C**, has received honoraria from and has acted as a consultant for Celgene, Takeda, Amgen, Bristol-Myers Squibb, and Novartis.

**Patricia A. Mangan, RN, MSN, APRN-BC**, has acted as a consultant for Celgene, Takeda, Amgen, Novartis, and Janssen, and has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, Amgen, and Novartis.

**Ali McBride, PharmD, MS, BCPS, BCOP**, has acted as a lecturer and served on speakers bureaus for Takeda.

**Ann McNeill, RN, MSN, APN**, has acted as a consultant for Celgene and Takeda and has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, Amgen, and Novartis.

**Teresa Miceli, RN, BSN, OCN**, has no potential conflicts of interest to disclose.

**Kimberly Noonan, RN, ANP, AOCN**, has served on the National MM Leadership Board.

**Tiffany Richards, MS, ANP, AOCNP**, has no potential conflicts of interest to disclose.

**Sandra Rome, RN, MN, AOCN, CNS**, has no potential conflicts of interest to disclose.

**Joseph Tariman, PhD, ANP-BC**, has acted as a lecturer and served on speakers bureaus for Celgene, Takeda, and Amgen.

**Daniel Verina, BS, BSN, MSN, ACNP-BC**, has acted as a lecturer and served on speakers bureaus for Celgene, Amgen, and Johnson & Johnson.

### ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

**John Bayliss, VP, Business Development at the Annenberg Center for Health Sciences at Eisenhower**, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

### LEAD NURSE PLANNER

**Sandra Kurtin, RN, MSN, AOCN, ANP-C**, has received honoraria from and has acted as a consultant for Celgene, Takeda, Amgen, Bristol-Myers Squibb, and Novartis.

### PLANNERS

**Jeannine Coronna** has nothing to disclose.

**Claudine Kiffer** has nothing to disclose.

**Sandra Kurtin, RN, MSN, AOCN, ANP-C**, has received honoraria from and has acted as a consultant for Celgene, Takeda, Amgen, Bristol-Myers Squibb, and Novartis.

**Larry Rosenberg** has nothing to disclose.

**Pamela Hallquist Viale, RN, MS, CNS, ANP**, has nothing to disclose.

## Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

## Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

## How to Earn Credit

To access the learning assessment and evaluation form online, visit <https://education.annenberg.net/5393>

**Statement of Credit:** Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.